Comparative Pharmacology
Head-to-head clinical analysis: AMINOCAPROIC ACID IN PLASTIC CONTAINER versus LYSTEDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOCAPROIC ACID IN PLASTIC CONTAINER versus LYSTEDA.
AMINOCAPROIC ACID IN PLASTIC CONTAINER vs LYSTEDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminocaproic acid is a lysine analog that binds to plasminogen and prevents its conversion to plasmin, thereby inhibiting fibrinolysis and stabilizing clots. It also inhibits plasmin directly at high doses.
Competitive inhibition of plasminogen activation, reducing fibrinolysis.
4-5 g IV over 1 hour followed by 1 g/h IV for 8 hours or until bleeding is controlled; max 30 g/24h.
650 mg orally three times daily (total 3.9 g/day) for up to 5 days during menses.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours in patients with normal renal function. In end-stage renal disease, half-life may be prolonged to 7-10 hours.
Terminal elimination half-life is approximately 2 hours (range 1.5–2.5 hours). In patients with renal impairment, half-life is significantly prolonged (up to 20 hours in severe renal impairment).
Primarily renal (approximately 80-90% excreted unchanged in urine via glomerular filtration).
Primarily renal excretion (>95% unchanged drug via glomerular filtration). Less than 5% is metabolized (mainly acylated derivative).
Category C
Category C
Antifibrinolytic
Antifibrinolytic